Oral levothyroxine is FDA approved for treating primary, secondary, and tertiary hypothyroidism.

Additionally, levothyroxine has FDA approval for pituitary thyrotropin suppression as an adjunct to surgery and radioiodine therapy to manage thyrotropin-dependent well-differentiated thyroid cancer.

Off-label usage of levothyroxine includes cadaveric organ recovery and subclinical hypothyroidism.